![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/05/17/2883983/0/en/HUTCHMED-Highlights-Sovleplenib-Phase-III-ESLIM-01-Study-and-Hematological-Malignancy-Programs-Data-to-be-Presented-at-the-upcoming-EHA2024-Congress.html
https://www.globenewswire.com//news-release/2024/01/11/2807571/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-for-Sovleplenib-for-the-Treatment-of-Primary-Immune-Thrombocytopenia-with-Priority-Review-Status.html
https://www.onclive.com/view/sovleplenib-elicits-durable-responses-in-primary-immune-thrombocytopenia
https://www.globenewswire.com//news-release/2023/08/21/2728359/0/en/HUTCHMED-Announces-that-the-Sovleplenib-Phase-III-ESLIM-01-Study-Met-Its-Primary-Endpoint-in-Primary-Immune-Thrombocytopenia-in-China.html
https://www.globenewswire.com/news-release/2023/01/03/2581851/0/en/HUTCHMED-Completes-Patient-Enrollment-of-ESLIM-01-a-Phase-III-Trial-of-Sovleplenib-in-Primary-Immune-Thrombocytopenia-in-China.html